Sermorelin Research: What the Studies Show
Sermorelin is a 29-amino-acid GHRH analog with an unusually long human record — it held FDA approval as Geref before being withdrawn in 2008 for commercial and manufacturing reasons, not safety. Here is what the published work actually measured.
Mechanism of action
Sermorelin is a synthetic 29-amino-acid fragment that reproduces the biologically active portion of growth hormone-releasing hormone (GHRH). It binds GHRH receptors on pituitary somatotrophs and stimulates transcription of growth hormone messenger RNA, so the pituitary manufactures and releases its own hGH.
Because release happens through the pituitary rather than by direct injection of hGH, secretion follows the body's natural pulsatile rhythm and the hypothalamic-pituitary negative feedback loop stays intact. That feedback ceiling is the mechanistic reason the compound is described as self-limiting in the literature.
Clinical reviews note that Sermorelin does not induce tachyphylaxis — the response does not fade with repeated administration — which is why it was used both therapeutically and as a provocative diagnostic agent for pituitary function.
The studies
Sermorelin's evidence base is older and clinically narrower than its wellness-market reputation suggests. Every trial below enrolled people with documented growth hormone deficiency or insufficiency; there is no large controlled trial in healthy adults with normal baseline IGF-1.
Growth hormone axis
Sermorelin for adult-onset growth hormone insufficiency
Whether stimulating the pituitary with a GHRH analog can restore growth hormone output in adults whose own hypothalamic GHRH signalling has declined with age.
Review of human clinical data on Sermorelin as replacement therapy for adult growth hormone insufficiency · 24-hour hGH profiling, peak GH amplitude and durability of response
- Increased
- Mean 24-hour hGH
- Amplified
- Peak GH release
- Not observed
- Tachyphylaxis
- Sermorelin raises endogenous growth hormone output by stimulating pituitary transcription of hGH mRNA rather than supplying the hormone directly.
- The response holds over repeated administration — the absence of tachyphylaxis is the practical argument for a secretagogue over direct hGH.
- Because the pituitary feedback loop is preserved, output is capped by physiology instead of by the injected dose.
Body composition & IGF-1
IGF-1 response and body composition change over 12 months
Whether the elevated growth hormone output translates into measurable fat loss and lean mass gain, and at what magnitude.
Trials in adults with documented growth hormone deficiency · serum IGF-1 at 12-16 weeks · lean mass and fat mass tracked to 12 months
- +35% to +50%
- IGF-1 at 12-16 weeks
- +1.5 to 2.0 kg (mean)
- Lean mass at 12 months
- -1.0 to 1.5 kg (mean)
- Fat mass at 12 months
- IGF-1 rises substantially and reliably, which is the biochemical confirmation that the pituitary is responding.
- The structural change is modest, not dramatic — roughly one to two kilograms in each direction over a full year, far below how the compound is marketed online.
- Every one of these trials enrolled adults with a documented deficiency. No major clinical trial has evaluated healthy adults with normal baseline IGF-1, so those figures cannot be assumed to transfer.
Metabolic profile
Metabolic markers and insulin sensitivity under secretagogue therapy
Whether a GHRH secretagogue can shift body composition without the deterioration in glucose control associated with direct hGH administration.
Tracking of metabolic markers, insulin sensitivity, general well-being and libido in men on growth hormone secretagogue therapy
- Improved
- Insulin sensitivity
- Improved
- Well-being and libido
- Not observed
- Glucose deterioration
- Direct hGH therapy is well known for provoking insulin resistance; working through the body's own feedback loop appears to avoid that penalty.
- Reported improvements extended beyond metabolism to general well-being and libido, though these are subjective endpoints.
- This is the strongest practical argument in the literature for a secretagogue over supplemental hGH.
Regulatory-era record
Diagnostic use and pediatric growth hormone deficiency (Geref era)
Establishing safety, dosing and whether pituitary somatotrophs respond reliably to a synthetic GHRH trigger.
FDA-approval pipeline data · Sermorelin as a provocative diagnostic agent for pituitary function and as therapy for idiopathic growth hormone deficiency in children · 30 mcg/kg daily subcutaneous
- 30 mcg/kg daily SC
- Pediatric dose established
- Stimulated
- Growth trajectory
- None established
- Long-term toxicity
- This is the reason Sermorelin has a longer human safety record than almost any other research peptide — it went through a full regulatory approval process.
- It confirmed that the pituitary responds to a synthetic analog essentially as it responds to natural hypothalamic GHRH.
- The Geref brand was withdrawn in 2008 for commercial and manufacturing reasons, not because of a safety finding.
Exploratory oncology
Sermorelin sensitivity in recurrent glioma
Whether Sermorelin interacts with tumour cell proliferation or immune signalling in high-grade recurrent brain tumours.
Analysis of recurrent glioma models and patient subgroups identified as Sermorelin-sensitive · receptor and growth factor expression, cell-cycle progression and local immune response
- Inhibited
- Tumour cell proliferation
- Blocked
- Cell cycle
- Increased
- Local immune response
- An unexpected line of research: a subset of recurrent glioma cases appears specifically sensitive to Sermorelin.
- The proposed action is down-regulation of particular receptors and growth factors, arresting the tumour cell cycle while local immune activity rises.
- This is exploratory work, not a treatment. It is included because it is part of the current literature, not because it supports any therapeutic use.
Storage & handling
Sermorelin is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water added slowly down the inner wall of the vial; swirl gently until dissolved and never shake.
Store reconstituted solution at 2-8 °C, protect from light, and use within your lab's defined stability window. Avoid repeated freeze-thaw cycles.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.